Safer nicotine wiki - User contributions [en-gb]

Center of Excellence for the acceleration of HArm Reduction

2022-10-31T15:38:43Z

CoEHAR: added link to the internal pages for DIasmoke and Replica Projects

__TOC__

=What is CoEHAR? =

[https://www.coehar.org Center of Excellence for the acceleration of Harm Reduction]. A unique multidisciplinary center focused on the study of Tobacco Harm Reduction. Innovation, peer-review research, and globalization of ideas are at the core of CoEHAR actions. '''CoEHAR is the International Center of Excellence for the acceleration of Harm Reduction''' established in 2018 within the '''Department of Clinical and Experimental Medicine of the University of Catania.'''

The Center’s main objective is to '''contribute to the global revolution''' through a multidisciplinary approach that helps to spread strategies and tools to reduce the harm caused by conventional cigarette smoke.

'''The CoEHAR council is made up of 40 academics'''<ref>{{Cite web|title=About Us - CoEHAR|url=https://www.coehar.org/about-us/|url-status=live}}</ref>, physicians, professors and technical operators of the University of Catania, from all the departments of the university, who work together and in connection with the world to make science and innovation.

CoEHAR includes the existing “Center for Tobacco prevention and treatment (CPCT)”, as well as the clinical setting of a local CRO and a selected network of cell and molecular biology as well as microbiology laboratories and will also act as a coordinating centre at a global level for scientific research, development of tech innovation, consolidation of existing research centers (particularly in LMIC), training and education, networking, and advocacy activities. In addition, '''the Center also collaborates with the Italian Anti-Smoking League - [[LIAF]] and [https://www.eclatrbc.it ECLAT]''', a spin-off founded within the University of Catania to make innovation transferrable.

CoEHAR's mission is to accelerate international scientific research efforts to reduce the impact of smoking on public health, helping to reduce the number of smoking deaths worldwide. Science, development and technological innovation, consolidation of existing research centers, training, education, advocacy and international partnerships are the main activities on which the CoEHAR excellence is based.

Among the most important projects promoted by CoEHAR are [[Replica]] and [[Diasmoke]].

=== Principal Activities ===
Main assets of the CoEHAR activity are:

# HARM REDUCTION is the principle on which our scientific approach is based. The use of alternative tools that are less harmful than conventional cigarette smoke (such as electronic cigarettes, snus and heated tobacco products) can reduce smoking damages. In fact, CoEHAR studies the factors that favor smoking addiction and identifies the most suitable tools for smoking cessation.
# Scientific and technological INNOVATION allows us to evaluate and promote solutions that are increasingly effective and less harmful than smoke. A creative and revolutionary scientific approach will guide us in studying the mechanisms that regulate smoking addiction with disruptive determination.
# The INTERNAZIONALIZATION of our scientific activities is the solid basis on which we develop the exchange of culture and knowledge. Thanks to a network of international collaborations we are able to create a new global science, shared and controlled, in order to improve every possible application of our findings, with specific solutions for the needs of every single country and territory.

CoEHAR multiple approaches in the fight against smoking are the foundation of its statute. From clinical research to educational projects, CoEHAR performs a holistic strategy to support goals.

[[Category:Harm-reduction]]
[[Category:Consumer Advocacy Organization]]
[[Category:Associated with TC/PH and THR]]

Riccardo Polosa

2022-10-31T15:38:13Z

CoEHAR: added a link to the internal page for LIAF

__TOC__

[https://en.wikipedia.org/wiki/Riccardo_Polosa Wikipedia Entry]

'''Riccardo Polosa''' is an Italian academic, who in 2018 described his roles as "Full Professor of Internal Medicine and specialist of Respiratory Diseases and Clinical Immunology at the University of Catania as well as the Founder and Clinical Director of the Center for Tobacco Research and Scientific Director of the Center of Excellence for the acceleration of HArm Reduction (CoEHAR) at the same University."<ref>[http://blogs.biomedcentral.com/on-health/2018/05/31/world-no-tobacco-day-mathieu-morissette-riccardo-polosa/ "World No Tobacco Day: Q&A with Mathieu Morissette and Riccardo Polosa"], 31 May 2018</ref>

He is full professor of Internal Medicine at the Department of Clinical and Experimental Medicine of the University of Catania<ref>{{Cite web|title=Riccardo Polosa|url=https://www.medclin.unict.it/faculty/riccardo.polosa|url-status=live}}</ref>, and an Italian Respiratory Physician, Clinical Immunologist, Allergist and Rheumatologist.<ref>{{Cite web|title=Reumatologia|url=https://www.unict.it/it/didattica/scuole-di-specializzazione/reumatologia|url-status=live}}</ref>

He is actively involved in smoking prevention and cessation. Indeed, he established the first Sicilian center for smoking cessation at the University of Catania in 2002.

In 2003, he founded the Italian Antismoking Association ([[LIAF]]), which he directed for 5 years.

In 2018, Polosa established, together with 38 academics, the [[Center of Excellence for the acceleration of HArm Reduction]] ([https://www.coehar.org CoEHAR]) at the University of Catania, a unique multi-disciplinary research centre with the mission to reduce health impacts and deaths from smoking, locally and globally.

In the area of in tobacco control and prevention, he has been the most prolific author in the field of electronic cigarettes – according to a paper published in BMC Public Health.<ref>{{Cite web|title=Worldwide research productivity in the field of electronic cigarette: a bibliometric analysis|url=https://bmcpublichealth.biomedcentral.com/articles/10.1186/1471-2458-14-667|url-status=live}}</ref> He is the lead author of ECLAT- first randomized controlled trial <ref>{{Cite web|title=EffiCiency and Safety of an eLectronic cigAreTte (ECLAT) as Tobacco Cigarettes Substitute: A Prospective 12-Month Randomized Control Design Study|url=https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0066317|url-status=live}}</ref> in the world about effectiveness and tolerability of e-cigarettes.

Replica

2022-10-31T15:37:32Z

CoEHAR: added a link to the internal page for Giovanni Li Volti

[https://replica.coehar.org Replica] is the First interlaboratory study in the world to replicate and validate high-profile studies on the cytotoxicity and inflammation induced by cigarette smoke and aerosol from electronic nicotine delivery systems (ENDS).

The Replica project team, directed by Prof. [[Giovanni Li Volti]] uses the most advanced tools and techniques and the most reliable methodologies to provide to the public with up-to-date information on ENDS.

In recent years, there has been an advancement in technologies capable to simulate human smoking and recreating closer physiological conditions for in vitro studies of smoke and aerosol cell exposure.

Based on these advancements Replica team of scientists has decided to replicate, for the first year of the study, three published works from the Tobacco Industry focusing on toxicological assessment and inflammation.

Giovanni Li Volti

2022-10-31T15:32:23Z

CoEHAR: Created a dedicated page for Prof. Giovanni Li Volti

[http://www.biometec.unict.it/docenti/giovanni.livolti Giovanni Li Volti] graduated from the School of Medicine of the University of Catania (Italy) in 2000 and obtained a PhD in Pediatric Sciences in 2005 in the same school.

He worked as a research associate from 2000 to 2002 at the Department of Pharmacology of the New York Medical College (USA). From 2005 to 2006 he was a post-doc at the Department of Anatomy of the University of Brescia (Italy).

During these years he worked extensively on oxidative stress and natural antioxidants under various experimental conditions both in vitro and in vivo. Since 2006 he is an associate professor of Biochemistry at the School of Pharmacy of the University of Catania where he continued his work on natural extracts and oxidative stress with particular regard to metabolic syndrome and neurodegenerative diseases.

Since 2019 he if a full professor of Biochemistry at the School of Medicine of the University of Catania where he serves as a deputy rector for biomedical research. Prof. Li Volti received several awards for his research including Aventis Pharma New Investigator Award for U.S. Fellow and Young Scientist Award FEBS meeting. He is also the recipient of various funded scientific grants related to oxidative stress and antioxidants.

He is the author of more than 230 peer-reviewed articles and he is currently serving as a member and associate editor in various high-ranked scientific journals (i.e. Journal of Clinical Medicine, Molecules, Frontiers in Pharmacology, Frontiers in Physiology, and many others).

He is currently ranked among the top Italian scientist in the world and his articles have been cited more than 5000 times (data from Scopus)

Diasmoke

2022-10-31T15:29:17Z

CoEHAR: created a dedicated page for diasmoke project

'''[https://diasmoke.coehar.org DIASMOKE]''' (Assessing the impact of combustion free-nicotine delivery technologies in Diabetic Smokers) '''is an international, multicenter, open-label randomized controlled study designed to determine wheter T2DM cigarette smokers switching to CF-NDS experience measurable improvement in cardiovascular risk parameters as a consequence of avoiding exposure to cigarette smoke toxicants.'''

Little is known about the impact of the combustion-free nicotine delivery system on T2DM patients who smoke.

This study aims to test the hypothesis that avoiding exposure to cigarette smoke toxicants may translate to measurable improvement in cardiovascular risk factors and functional parameters when type 2 diabetes mellitus (T2DM) patients who smoke switch to using C-F NDS compared with T2DM patients who continue to smoke conventional tobacco products.

Replica

2022-10-31T15:27:13Z

CoEHAR: Created a dedicated page for Replica Project

[https://replica.coehar.org Replica] is the First interlaboratory study in the world to replicate and validate high-profile studies on the cytotoxicity and inflammation induced by cigarette smoke and aerosol from electronic nicotine delivery systems (ENDS).

The Replica project team, directed by Prof. Giovanni Li Volti uses the most advanced tools and techniques and the most reliable methodologies to provide to the public with up-to-date information on ENDS.

In recent years, there has been an advancement in technologies capable to simulate human smoking and recreating closer physiological conditions for in vitro studies of smoke and aerosol cell exposure.

Based on these advancements Replica team of scientists has decided to replicate, for the first year of the study, three published works from the Tobacco Industry focusing on toxicological assessment and inflammation.

Riccardo Polosa

2022-10-31T15:13:36Z

CoEHAR: added internal link for liaf

__TOC__

[https://en.wikipedia.org/wiki/Riccardo_Polosa Wikipedia Entry]

=About=

'''Riccardo Polosa''' is an Italian academic, who in 2018 described his roles as "Full Professor of Internal Medicine and specialist of Respiratory Diseases and Clinical Immunology at the University of Catania as well as the Founder and Clinical Director of the Center for Tobacco Research and Scientific Director of the Center of Excellence for the acceleration of HArm Reduction (CoEHAR) at the same University."<ref>[http://blogs.biomedcentral.com/on-health/2018/05/31/world-no-tobacco-day-mathieu-morissette-riccardo-polosa/ "World No Tobacco Day: Q&A with Mathieu Morissette and Riccardo Polosa"], 31 May 2018</ref>

He is full professor of Internal Medicine at the Department of Clinical and Experimental Medicine of the University of Catania<ref>{{Cite web|title=Riccardo Polosa|url=https://www.medclin.unict.it/faculty/riccardo.polosa|url-status=live}}</ref>, and an Italian Respiratory Physician, Clinical Immunologist, Allergist and Rheumatologist.<ref>{{Cite web|title=Reumatologia|url=https://www.unict.it/it/didattica/scuole-di-specializzazione/reumatologia|url-status=live}}</ref>

He is actively involved in smoking prevention and cessation. Indeed, he established the first Sicilian center for smoking cessation at the University of Catania in 2002.

In 2003, he founded the [[Italian Antismoking Association (LIAF)]], which he directed for 5 years.

In 2018, Polosa established, together with 38 academics, the [[Center of Excellence for the acceleration of HArm Reduction]] ([https://www.coehar.org CoEHAR]) at the University of Catania, a unique multi-disciplinary research centre with the mission to reduce health impacts and deaths from smoking, locally and globally.

In the area of in tobacco control and prevention, he has been the most prolific author in the field of electronic cigarettes – according to a paper published in BMC Public Health.<ref>{{Cite web|title=Worldwide research productivity in the field of electronic cigarette: a bibliometric analysis|url=https://bmcpublichealth.biomedcentral.com/articles/10.1186/1471-2458-14-667|url-status=live}}</ref> He is the lead author of ECLAT- first randomized controlled trial <ref>{{Cite web|title=EffiCiency and Safety of an eLectronic cigAreTte (ECLAT) as Tobacco Cigarettes Substitute: A Prospective 12-Month Randomized Control Design Study|url=https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0066317|url-status=live}}</ref> in the world about effectiveness and tolerability of e-cigarettes.

LIAF

2022-10-31T15:12:02Z

CoEHAR: added a page for liaf

[https://www.liaf-italia.it LIAF – the Italian Anti Smoking League] - is a no-profit organization working for spreading “antismoking culture”, raising public awareness with respect to the harm caused by tobacco smoking.

Our non-profit organization aims to concretely help smokers to quit smoking, enhancing smoking cessation programs and increasing research studies conducted in this field.

Thanks to the work of a team of international experts, LIAF has been able to achieve excellent results in scientific dissemination, smokers involvements, and support to research.

Since 2010, LIAF is engaged in the study of electronic cigarettes as a less harmful alternative to tobacco smoking. Our support to scientific studies has helped to demonstrate the effectiveness and efficiency of e-cigs as a tool to reduce or stop smoking.

Riccardo Polosa

2022-10-31T15:03:47Z

CoEHAR: added important details about the career and studies of Riccardo Polosa

__TOC__

[https://en.wikipedia.org/wiki/Riccardo_Polosa Wikipedia Entry]

=About=

'''Riccardo Polosa''' is an Italian academic, who in 2018 described his roles as "Full Professor of Internal Medicine and specialist of Respiratory Diseases and Clinical Immunology at the University of Catania as well as the Founder and Clinical Director of the Center for Tobacco Research and Scientific Director of the Center of Excellence for the acceleration of HArm Reduction (CoEHAR) at the same University."<ref>[http://blogs.biomedcentral.com/on-health/2018/05/31/world-no-tobacco-day-mathieu-morissette-riccardo-polosa/ "World No Tobacco Day: Q&A with Mathieu Morissette and Riccardo Polosa"], 31 May 2018</ref>

He is full professor of Internal Medicine at the Department of Clinical and Experimental Medicine of the University of Catania<ref>{{Cite web|title=Riccardo Polosa|url=https://www.medclin.unict.it/faculty/riccardo.polosa|url-status=live}}</ref>, and an Italian Respiratory Physician, Clinical Immunologist, Allergist and Rheumatologist.<ref>{{Cite web|title=Reumatologia|url=https://www.unict.it/it/didattica/scuole-di-specializzazione/reumatologia|url-status=live}}</ref>

He is actively involved in smoking prevention and cessation. Indeed, he established the first Sicilian center for smoking cessation at the University of Catania in 2002.

In 2003, he founded the Italian Antismoking Association (LIAF), which he directed for 5 years.

In 2018, Polosa established, together with 38 academics, the [[Center of Excellence for the acceleration of HArm Reduction]] ([https://www.coehar.org CoEHAR]) at the University of Catania, a unique multi-disciplinary research centre with the mission to reduce health impacts and deaths from smoking, locally and globally.

In the area of in tobacco control and prevention, he has been the most prolific author in the field of electronic cigarettes – according to a paper published in BMC Public Health.<ref>{{Cite web|title=Worldwide research productivity in the field of electronic cigarette: a bibliometric analysis|url=https://bmcpublichealth.biomedcentral.com/articles/10.1186/1471-2458-14-667|url-status=live}}</ref> He is the lead author of ECLAT- first randomized controlled trial <ref>{{Cite web|title=EffiCiency and Safety of an eLectronic cigAreTte (ECLAT) as Tobacco Cigarettes Substitute: A Prospective 12-Month Randomized Control Design Study|url=https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0066317|url-status=live}}</ref> in the world about effectiveness and tolerability of e-cigarettes.

Center of Excellence for the acceleration of HArm Reduction

2022-10-05T13:41:49Z

CoEHAR: I add more specific information about the center

__TOC__

=What is CoEHAR? =

Center of Excellence for the acceleration of Harm Reduction. A unique multidisciplinary center focused on the study of Tobacco Harm Reduction. Innovation, peer-review research, and globalization of ideas are at the core of CoEHAR actions. '''CoEHAR is the International Center of Excellence for the acceleration of Harm Reduction''' established in 2018 within the '''Department of Clinical and Experimental Medicine of the University of Catania.'''

The Center’s main objective is to '''contribute to the global revolution''' through a multidisciplinary approach that helps to spread strategies and tools to reduce the harm caused by conventional cigarette smoke.

'''The CoEHAR council is made up of 40 academics''', physicians, professors and technical operators of the University of Catania, from all the departments of the university, who work together and in connection with the world to make science and innovation.

CoEHAR includes the existing “Center for Tobacco prevention and treatment (CPCT)”, as well as the clinical setting of a local CRO and a selected network of cell and molecular biology as well as microbiology laboratories and will also act as a coordinating centre at a global level for scientific research, development of tech innovation, consolidation of existing research centers (particularly in LMIC), training and education, networking, and advocacy activities. In addition, '''the Center also collaborates with the Italian Anti-Smoking League - LIAF and ECLAT''', a spin-off founded within the University of Catania to make innovation transferrable.

https://www.coehar.org/

[[Catogory: Harm-reduction]]